Table 1.
Baseline patient and disease characteristics.
| Characteristic | N | Median (q1-q3) or % |
|---|---|---|
| Age at diagnosis (years) | 39 | 61 (59, 65) |
| Gleason score at diagnosis | ||
| ≤ 6 | 6 | 15% |
| 7 | 14 | 35% |
| ≥ 8 | 18 | 45% |
| Unknown | 2 | 5% |
| Prior radical prostatectomy | 20 | 50% |
| Prior radiation therapy | 21 | 53% |
| Prior chemotherapy | 7 | 18% |
| Prior ketoconazole | 10 | 25% |
| Median duration of ketoconazole | 10 | 2.5 months (range <1–25 months) |
| Prior enzalutamide | 4 | 10% |
| Median duration of enzalutamide | 4 | 5 months (range 2–18 months) |
| At therapy initiation | ||
| Age (years) | 40 | 69 (65, 74) |
| Sites of metastasis | ||
| Bone metastases | 32 | 80% |
| Lymph nodes | 11 | 28% |
| Liver | 2 | 5% |
| Lung | 1 | 3% |
| ECOG performance status | ||
| 0 | 34 | 85% |
| 1 | 6 | 15% |
| Laboratory data | ||
| PSA (ng/mL) | 40 | 28.8 (9.5, 74.0) |
| Testosterone (ng/dL) | 40 | 10 (7, 12.5) |
| Alkaline phosphatase (U/L) | 40 | 89.5 (67.5, 153.5) |
| Calcium (mg/dL) | 34 | 9.4 (9.1, 9.7) |
| Hemoglobin (g/dL) | 40 | 13.2 (12.5, 14.0) |
| Platelets (K/UL) | 40 | 230 (186.5, 255) |
ECOG=Eastern Oncology Cooperative Group, PSA=prostate specific antigen.